Biomarin Pharmaceutical (BMRN) Cost of Revenue (2009 - 2026)

Biomarin Pharmaceutical's Cost of Revenue history runs 18 years deep, the most recent figure standing at $195.0 million for Q1 2026.

• Quarterly Cost of Revenue rose 28.66% year-over-year to $195.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $760.9 million (up 25.43% YoY) and the FY2025 annual result came in at $717.4 million, up 23.65% from the prior year.
• Cost of Revenue was $195.0 million for Q1 2026 at Biomarin Pharmaceutical, down from $275.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $275.7 million in Q4 2025 and bottomed at $116.3 million in Q3 2022.
• A 5-year average of $148.7 million and a median of $136.1 million in 2024 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 102.52% in 2025, while the deepest fall reached 25.67% in 2025.
• Biomarin Pharmaceutical's Cost of Revenue stood at $146.6 million in 2022, then dropped by 5.94% to $137.9 million in 2023, then slipped by 1.3% to $136.1 million in 2024, then surged by 102.52% to $275.7 million in 2025, then declined by 29.27% to $195.0 million in 2026.
• Business Quant data shows BMRN's Cost of Revenue at $195.0 million in Q1 2026, $275.7 million in Q4 2025, and $140.1 million in Q3 2025.